Should I Buy CHCI? CHCI 2026 Analysis

Should You Buy Comstock Holding Companies Inc (CHCI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

11.180

1 Day change

-2.61%

52 Week Range

18.990

Analysis Updated At

2026/01/28

CHCI is not a good buy right now for a beginner, long-term investor with $50k–$100k who wants to act immediately. Price action is neutral and close to support, but the latest quarter shows sharp profitability and margin deterioration, and there are no proprietary buy signals to override that. The better decision today is to stay on the sidelines (hold/avoid initiating).

Technical Analysis

Trend/price context: CHCI is $11.25 (+0.39%) and trading below the pivot (11.873), which keeps near-term momentum muted. Indicators: MACD histogram is positive (0.0881) but contracting, suggesting bullish pressure is weakening rather than strengthening. RSI(6) ~51 is neutral. Moving averages are converging, consistent with consolidation/no clear trend. Levels: Support S1 ~10.704 (then S2 ~9.981). Resistance R1 ~13.041 (then R2 ~13.764). With price below pivot and no strong momentum signal, the setup is more “range-bound/indecisive” than a clean long-term entry.

Options Data

Positive Catalysts

could limit downside in the very near term. Revenue grew +2.48% YoY in 2025/Q3, showing top-line resilience. Pattern-based projection cited: ~9.22% chance/expectation in the next month (model-based, not guaranteed). Upcoming earnings (2026-02-12 after hours) can act as a catalyst if results re-accelerate profitability. Trading trends: Hedge funds neutral; insiders neutral (no notable recent activity).

Neutral/Negative Catalysts

Latest quarter profitability weakened sharply: 2025/Q3 net income -77.24% YoY, EPS -78.26% YoY, and gross margin fell to 10.41 (-59.43% YoY), signaling significant margin pressure. Technicals are not confirming an uptrend (MACD contracting, RSI neutral, price below pivot). No news flow in the last week to support a momentum bid. Earnings on 2026-02-12 could also disappoint given the margin trend, which is a key near-term risk driver.

Financial Performance

2025/Q3: Revenue was $13.317M (+2.48% YoY), but profitability deteriorated materially—Net Income $0.541M (-77.24% YoY), EPS $0.05 (-78.26% YoY). Gross margin dropped to 10.41 (-59.43% YoY). Overall: modest revenue growth but sharply worsening margins/earnings, a negative growth-quality trend for a long-term buy decision today.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price-target data was provided, implying limited visibility into Wall Street consensus. Pros view cannot be confirmed from the dataset. From the data we do have: the main bull case would be a rebound in margins/earnings into upcoming quarters; the main bear case is that margin compression is structural and keeps EPS pressured. Politicians/congress: no recent congress trading data available.

Analyst Rating

Wall Street analysts forecast CHCI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHCI is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 11.480

Low

Averages

High